Pharmaceutical company GlaxoSmithKline is planning a commercial reboot to streamline their budget, potentially generating budget savings of 20%.
Do the Public Need a Good Understanding of Genomics?
Do the Public Need a Good Understanding of Genomics?There is a disconnect between scientists and the public when it comes to genomics. What is the public’s understanding of genomics and why is this important?
Pharma Unit Overhaul for GSK
Pharma Unit Overhaul for GSKPharmaceutical company GlaxoSmithKline is planning a commercial reboot to streamline their budget, potentially generating budget savings of 20%.
Rare Genetic Mutations May Cause More Diseases Than We Think
Rare Genetic Mutations May Cause More Diseases Than We ThinkNew research suggests that many people’s health problems brought on by single-gene mutations are getting misdiagnosed.
Celgene Opposes Trend to Strengthen Neuroscience Pipeline
Celgene Opposes Trend to Strengthen Neuroscience PipelineGoing against industry trend of backing out of the neuroscience field, is Celgene, who is about to put down a potential $2.2 million to gain options on three Prothena drug candidates.
Color's New DNA Test Will Tell You If You're at Risk of Heart Disease—Or Not
Color's New DNA Test Will Tell You If You're at Risk of Heart Disease—Or NotColor's new DNA test identifies inherited heart conditions, where the idea is for customers to work with their doctor to come up with a plan to detect conditions early and prevent medical problems.
New research suggests that many people’s health problems brought on by single-gene mutations are getting misdiagnosed.
Going against industry trend of backing out of the neuroscience field, is Celgene, who is about to put down a potential $2.2 million to gain options on three Prothena drug candidates.
Color’s new DNA test identifies inherited heart conditions, where the idea is for customers to work with their doctor to come up with a plan to detect conditions early and prevent medical problems.
Scientists are bringing precision medicine to rheumatoid arthritis for the first time by using genetic profiling of joint tissue to see which drugs will work for which patients.
Healthcare tech startup Theranos was riding high back in 2014. But when a reporter raised questions, its media reps circled the wagons.
There is a disconnect between scientists and the public when it comes to genomics. What is the public’s understanding of genomics and why is this important?
Following on from our feature last week, that discussed the ‘origin of life’, we sat down with George Church, a project supporter, to find hear his thoughts.
As it’s Rare Disease Day, we’ve put together some relevant resources from The American Society of Human Genetics (ASHG) on pediatric testing.
The Short Read
“How Can We Anticipate and Respond to Technologies and Information That is Rapidly Changing?” – Josephine Johnston
Josephine Johnston is an expert on the ethical, legal and policy implications of biomedical technologies, particularly as used in human reproduction, psychiatry, genetics, and neuroscience.
“I Would Like to See Widespread Reimbursement of Clinical Genomic Testing as Well as Screening” – Gavin Stone
Gavin Stone is an electronics engineer who joined Edico Genome in 2013 to lead corporate development and marketing for the DRAGEN™ Bio-IT Processor, the world’s first next-generation sequencing bioinformatics chip to massively speed up genomic medicine.
“It’s Through Community Outreach & Education We Ensure Continued Public Commitment” – Hsiao-Tuan Chao
Hsiao-Tuan Chao is a physician-scientist in the field of child neurology, we’ve had a chat with her in this week’s Short Read.
Magazines and Educational Guides
In this issue of the magazine, we talk all things ACMG, and speak to some of the most prolific figures in the industry.
Free download: This guide is designed to introduce you to how genomics is being integrated into the clinic, what goes into using a patient’s DNA to reach a diagnosis, and how this information can be communicated to primary care physicians.
We bring genomics to the UK in our latest issue, as we look ahead to what this year’s Festival of Genomics London has to offer.
We surveyed a cross-section of the international genomics workforce to find out which jobs, and where, are typically best paid; whether or not the gender pay gap still exists; what attracts people to their jobs; and where those people are coming from.
What’s blockchain technology, how, and why was it developed, and why is everyone talking about it? Alex Schmid provides us with an overview of challenges blockchain technology can help solve within life sciences, and what about it, that makes it so suitable.
Just as sequencing has been getting faster, so too has library preparation. The process can be broadly broken up into 5-6 main stages, depending on method.
Learn more about Edico Genome’s new DRAGEN Virtual Long-Read Detection (VLRD) Pipeline, that’s the first variant caller dedicated to SDs, and is designed to run with short sequence reads generated at moderate coverage.
With do-it-yourself CRISPR kits now available online, Hannah Devlin asks if it’s really possible to edit your own DNA, is it safe and how should it be regulated?
A discussion of the technology that is in use today that allows Metabolon to carry out n of 1 studies that enable precision medicine, as well as future technology. Available on-demand.
Around the Web
ArcherDX, a company known for producing NGS-based gene fusion detection assays, has closed a $35 million Series A preferred financing,
Designed to accelerate pre-clinical genomic research and drug discovery for the benefit of patients, the team behind the global genomic data marketplace has grown by nearly 50% in the past year.
New research shows that a test for measuring the length of DNA endcaps called telomeres can alter treatment decisions for patients with certain types of bone marrow failures.
The promise of precision medicine is replacing the one-size-fits-all medicine of the past. Doctors hope this will make everyone healthier. But a new report says certain groups in the US are in jeopardy of being worse off when medicine is tailor-made. Who stands to lose?
This is 2018 guys; people are injecting stem cells into their penises hoping to make them bigger, and having their cheeks swabbed hoping to find the one. What’s going on?
A USD $5 million technology prize aims to crack the origin of the genetic code. The Evolution 2.0 Prize was announced at Arizona State University in August 2017. The largest “origin of life” prize to date, it seeks to bridge the gap between chemistry, genomics and modern computing.